Alivus Life Sciences Ltd announced consolidated revenue from operations of ₹6.73 billion and net profit of ₹1.5 billion for the December quarter. The results highlight steady growth in pharmaceutical manufacturing and exports, reflecting strong demand, operational efficiency, and resilience in India’s evolving healthcare sector.
Alivus Life Sciences Ltd has reported a consolidated revenue of ₹6.73 billion for the quarter ended December 2025, alongside a net profit of ₹1.5 billion. The results underscore the company’s ability to sustain growth momentum in a competitive pharmaceutical landscape, driven by robust demand across domestic and international markets.
Key highlights of the quarterly performance:
-
Revenue of ₹6.73B reflects expanding product portfolio and strong export contributions, particularly in specialty formulations.
-
Net profit of ₹1.5B signals effective cost management and operational efficiency, despite rising input costs in the pharma sector.
-
Analysts note that Alivus has been focusing on innovation and R&D investments, strengthening its pipeline of critical therapies.
-
The company’s performance aligns with India’s broader pharmaceutical growth story, where global demand for affordable generics and specialty drugs continues to rise.
-
Market watchers emphasize that Alivus’ results highlight its balanced approach to growth and sustainability, positioning it well for long-term expansion.
Industry experts believe Alivus Life Sciences’ Q3 earnings reinforce its role as a key contributor to India’s healthcare ecosystem, combining profitability with innovation and global competitiveness.
Sources: Reuters, Economic Times Pharma Desk, Mint, NSE Corporate Filings